Alkermes ALKS
NASDAQ ALKS
$43.75 -0.36 (-0.82%)
As of: Oct 21, 2026 · 12:47 PM EDT

Alkermes (ALKS) Accumulated Expenses (2012 - 2013)

Updated

Analysis

Alkermes (ALKS) Accumulated Expenses (2012 - 2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,132.21 Bn 1,100.80 Bn 19.71 Bn
2 Johnson & Johnson 616.27 Bn 534.80 Bn 17.26 Bn
3 AbbVie 500.10 Bn 473.21 Bn 12.70 Bn
4 Merck 366.86 Bn 321.23 Bn 12.21 Bn
5 Novartis Ag 297.92 Bn 261.91 Bn 11.24 Bn
6 Astrazeneca 261.53 Bn 235.22 Bn 12.86 Bn
7 Amgen 234.99 Bn 190.39 Bn 7.24 Bn
8 Gilead Sciences 190.14 Bn 164.34 Bn 6.22 Bn
9 Pfizer 169.63 Bn 116.28 Bn 10.94 Bn
10 Alkermes 7.31 Bn 4.44 Bn 397.90 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2013 934,000.00
Jun 30, 2013 939,000.00
Mar 31, 2013 970,000.00
Dec 31, 2012 1.31 Mn
Sep 30, 2012 275,000.00
Jun 30, 2012 2.46 Mn
Mar 31, 2012 2.47 Mn
API Access

Alkermes Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=ALKS&period=max&api_key=YOUR_API_KEY